证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2019-04 | --- | --- | --- | |----------------|-----------------------------|----------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 广发证券股份有限公司 李东升 | | | 人员姓名 | 永赢基金管理有限公司 焦阳 | | | | 永赢基金管理有限公司 安福延 | | | | 中海基金管理有限公司 梁静静 | | | 时间 | 2019 年 11 月 | 22 日 | | 地点 | 上海市浦东新区瑞庆路 | 528 号公司四楼会议室 | | 上市公司接待人 | | 上海凯利泰医疗科技股份有限公司 董事会秘书 ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2017-01 | --- | --- | --- | |----------------|-------------------------------|-----------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国金证券股份有限公司 孙笑悦 | | | 人员姓名 | | 承珞（上海）投资管理中心有限合伙 林田心 | | | 德邦证券股份有限公司 陈国栋 | | | | 上海证券有限责任公司 路傅懿 | | | | | 上海东方证券创新投资有限公司 毕海委 | | | 上海听畅资本有限公司 王一鸣 | | | | 上海世诚投资管理有限公司 夏骏 | | | | 上海致君资产管理有限公司 李涛 | | ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2018-01 | --- | --- | --- | |----------------|-----------------------------------|------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中国国际金融股份有限公司 邹朋 | | | 人员姓名 | 中国国际金融股份有限公司 张琎 | | | | 交银施罗德基金管理有限公司 楼慧源 | | | | 国投瑞银基金管理有限公司 谢允昌 | | | | 国投瑞银基金管理有限公司 张佳荣 | | | 时间 | 2018 年 6 月 5 日 | | | 地点 | 上海市浦东新区瑞庆路 | 528 号公司四楼会议室 | ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2018-03 | --- | --- | --- | |----------------|-----------------------------------|------------| | | | | | 投资者关系活动 | √ 特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | 路演活动 | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 国金证券股份有限公司 袁维 | | | 人员姓名 | 富国基金管理有限公司 张啸伟 | | | | 上海沣杨资产管理有限公司 张秀磊 | | | | 上海常春藤资产管理有限公司 刘涛 | | | | 紫金财产保险股份有限公司 周路 | | | | 上海汐泰投资管理有限公司 冯时 | | | | 上海肇万资产管理有限公司 李方勇 | | | | 德邦证券股份有限公司 陈国栋 | | | 时间 | 2018 年 11 月 16 日 | | 1 | --- ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2018-02 | --- | --- | --- | |----------------|-----------------------------------|--------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 招商证券股份有限公司 漆经纬 | | | 人员姓名 | 招商证券股份有限公司 李莎 | | | | 江海证券股份有限公司 李希 | | | | 上海复杉投资管理有限公司 徐璐瑶 | | | | 圆信永丰基金管理有限公司 范习辉 | | | | 富舜资产管理有限公司 陈洪 | | | | 上海正享投资管理有限公司 况弘 | | | | 金库骐楷投资管理有限公司 黄隆堂 | | 1 | --- | --- | |------------- ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2018-03 | --- | --- | --- | |----------------|-----------------------------------|------------| | | | | | 投资者关系活动 | √ 特定对象调研 | 分析师会议 | | 类别 | □ 媒体采访 | 业绩说明会 | | | □ 新闻发布会 | 路演活动 | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 国金证券股份有限公司 袁维 | | | 人员姓名 | 富国基金管理有限公司 张啸伟 | | | | 上海沣杨资产管理有限公司 张秀磊 | | | | 上海常春藤资产管理有限公司 刘涛 | | | | 紫金财产保险股份有限公司 周路 | | | | 上海汐泰投资管理有限公司 冯时 | | | | 上海肇万资产管理有限公司 李方勇 | | | | 德邦证券股份有限公司 陈国栋 | | | 时间 | 2018 年 11 月 16 日 | | 1 | --- ...

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2018-04 | --- | --- | --- | |----------------|---------------------------|---------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安信证券股份有限公司 马帅 | | | 人员姓名 | | 景顺长城基金管理有限公司 刘晓明 | | | | 景顺长城基金管理有限公司 詹成 | | | | 景顺长城基金管理有限公司 余广 | | | | 景顺长城基金管理有限公司 姜雪婷 | | | | 景顺长城基金管理有限公司 余捷涛 | | 时间 | 2018 年 11 月 | 26 日 | | 地点 | 上海市浦东新区瑞庆路 | 528 号公司四楼会议室 | 1 | ...

Financial Performance - The company's revenue for Q3 2022 was ¥326,173,926.53, a decrease of 3.25% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥64,183,017.81, down 24.93% year-on-year[6]. - The basic earnings per share for Q3 2022 was ¥0.0892, reflecting a decline of 24.53% compared to the previous year[6]. - Total operating revenue for Q3 2022 was ¥928.39 million, a decrease of 4.54% from ¥972.79 million in Q3 2021[38]. - Net profit for Q3 2022 was ¥198.37 million, a decline of 6.15% compared to ¥211.42 million in Q3 2021[40]. - Operating profit for the period was ¥223.52 million, down 6.79% from ¥239.89 million in the same period last year[38]. - The company’s total profit for the period was ¥228.30 million, a decrease of 5.12% from ¥240.45 million in Q3 2021[40]. Cash Flow - The company reported a decrease in cash flow from operating activities by 9.39% year-to-date, totaling ¥244,700,394.94[6]. - The net cash flow from operating activities for the period was 24,470.04 million RMB, a decrease of 2,535.92 million RMB or 9.39% compared to the same period last year, primarily due to reduced sales revenue and collection of payments influenced by national medical device procurement policies[24]. - The net cash flow from investing activities was -11,419.91 million RMB, a decrease of 712.21 million RMB or 6.65% year-on-year, mainly due to a reduction in cash received from investment income and the disposal of fixed assets[25]. - The net cash flow from financing activities was -20,282.17 million RMB, a decrease of 6,306.53 million RMB or 45.13% compared to the previous year, primarily due to a decrease in cash received from borrowings[26]. - Total cash inflow from operating activities was 109,324.37 million RMB, down 10.82% from 122,586.48 million RMB in the previous year[23]. - Total cash outflow from operating activities was 84,854.33 million RMB, a decrease of 11.22% from 95,580.52 million RMB in the previous year[23]. - The company reported a net cash outflow from investing activities of ¥114.20 million, compared to a net outflow of ¥107.08 million in the previous year[43]. - The net cash flow from financing activities was -¥202,821,766.13, compared to -¥139,756,348.87 in the previous year, indicating a decline of approximately 45%[44]. - The cash flow from operating activities showed a significant outflow, with total cash outflow from financing activities amounting to ¥335,967,239.35, compared to ¥413,299,558.87 in the previous year[44]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,586,879,579.52, an increase of 2.21% from the end of the previous year[6]. - The company reported a total asset of CNY 3,586,879,579.52 as of September 30, 2022, an increase from CNY 3,509,475,704.32 at the beginning of the year[36]. - The total liabilities decreased to CNY 543,611,351.86 from CNY 731,099,383.73, a reduction of about 25.7%[37]. - The company's equity attributable to shareholders increased to CNY 2,969,743,445.01 from CNY 2,733,520,373.23, reflecting an increase of approximately 8.6%[37]. - The company’s total equity attributable to shareholders increased by 8.64% to ¥2,969,743,445.01 compared to the previous year[6]. Operational Changes - The company is actively communicating with distributors to assess the impact of centralized procurement policies on its existing distribution system[34]. - The centralized procurement for orthopedic spinal products was officially launched on July 11, 2022, with 14 product system categories established for procurement[33]. - The company plans to complete the assessment of the impact of centralized procurement policies on its financial data by the fourth quarter of 2022[34]. - The company is adjusting its operational strategies in response to the significant price reductions resulting from centralized procurement policies[34]. Other Income and Expenses - The company reported a 37.49% decrease in other income year-to-date, totaling ¥1,505.58 million[19]. - The company experienced a significant increase in other comprehensive income, which rose by 182.96% to ¥3,398.23 million, attributed to foreign exchange fluctuations[16]. - Other comprehensive income after tax was ¥74.95 million, compared to a loss of ¥3.87 million in the same period last year[40]. Inventory and Receivables - The company's cash and cash equivalents decreased to CNY 671,652,932.39 from CNY 729,026,805.82 at the start of the year, reflecting a decline of approximately 7.5%[36]. - The accounts receivable decreased to CNY 421,340,591.73 from CNY 453,914,327.85, indicating a reduction of about 7.2%[36]. - The company's inventory increased to CNY 317,535,559.84 from CNY 293,600,675.89, representing an increase of approximately 8.1%[36].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥602.21 million, a decrease of 5.26% compared to ¥635.67 million in the same period last year[19]. - The net profit attributable to shareholders increased by 16.65% to approximately ¥132.63 million, up from ¥113.70 million in the previous year[19]. - The net profit after deducting non-recurring gains and losses rose by 21.11% to approximately ¥126.01 million, compared to ¥104.05 million in the same period last year[19]. - Basic earnings per share rose by 17.10% to ¥0.1842, compared to ¥0.1573 in the same period last year[19]. - The company's operating revenue for the reporting period was ¥602,212,936.76, a decrease of 5.26% compared to ¥635,674,828.80 in the same period last year, primarily due to the impact of the COVID-19 pandemic in the Shanghai area and a significant reduction in medical disinfection service revenue and trade business income[54]. - The company reported a total profit of CNY 150.83 million, a rise of 11.9% compared to CNY 135.21 million in the first half of 2021[182]. - The net profit margin for the period was approximately 10%, showcasing effective cost management strategies[196]. Cash Flow and Investments - The net cash flow from operating activities increased by 26.30% to approximately ¥137.78 million, compared to ¥109.08 million in the previous year[19]. - The net cash flow from investing activities decreased by 24.71% to -¥83.99 million, mainly due to a reduction in cash paid for fixed assets and other investments by ¥36.88 million[55]. - The net cash flow from financing activities increased by 29.97% to -¥61.82 million, attributed to a decrease in cash paid for debt repayment by ¥76.21 million[56]. - The total cash and cash equivalents at the end of the period stood at CNY 727,740,494.95, compared to CNY 647,019,143.43 at the end of the first half of 2021, reflecting an increase of 12.5%[190]. - The company reported a net increase in cash and cash equivalents of CNY 47,340,036.19 for the first half of 2022, compared to an increase of CNY 37,389,843.88 in the same period of 2021[193]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥3.61 billion, an increase of 2.88% from ¥3.51 billion at the end of the previous year[19]. - The total liabilities at the end of the reporting period were 3.8 billion, which is a 4.4% increase year-over-year[200]. - Cash and cash equivalents at the end of the reporting period amounted to ¥727,740,494, accounting for 20.16% of total assets, a decrease of 0.61% compared to the previous year[60]. - The company's long-term equity investments decreased to CNY 197,029,031.50 from CNY 201,335,495.25, a decline of approximately 2.13%[175]. Research and Development - Research and development expenses increased by 29.76% to ¥34,186,878.39 from ¥26,345,825.88, reflecting a commitment to innovation and product development[54]. - The company aims to increase its R&D investment by 15% in the upcoming fiscal year to drive innovation[197]. - The company is actively pursuing market expansion in regions such as Egypt, the Philippines, and Belarus for its new product lines[51]. - The company has ongoing research and development efforts in new medical technologies and products[69]. Market Strategy and Expansion - The company has successfully expanded its product line from a single spinal product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products[27]. - Following the acquisition of Aideer, the company optimized and integrated the orthopedic product lines and sales channels, enhancing its core competitiveness and ensuring sustainable growth[31]. - The company aims to focus on the development of minimally invasive orthopedic products, particularly through its dual-brand strategy with Aideer[27]. - The company is exploring potential mergers and acquisitions to accelerate growth and market penetration[197]. - The company is focused on expanding innovative minimally invasive products across multiple departments in the future[47]. Quality Control and Compliance - The company emphasizes strict quality control as a competitive advantage, investing significant resources in quality management and training[46]. - The company adheres to national regulations in establishing a complete quality system, ensuring compliance in all operational stages[46]. - The company emphasizes product quality control and has not faced any product liability claims or related legal issues to date[95]. Shareholder and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[4]. - The company held its first temporary shareholders' meeting on February 22, 2022, with an investor participation rate of 17.93%[113]. - The annual shareholders' meeting for 2021 was held on June 8, 2022, with a participation rate of 19.72%[113]. - The company has implemented a management incentive plan that includes restricted stock awards[157]. Social Responsibility - The company emphasizes its commitment to social responsibility and aims to contribute to public health initiatives[123]. - The company donated medical equipment worth over 7 million RMB to the Bethune Foundation to support flood relief efforts in Henan Province[124]. - The company, along with its subsidiaries, raised and donated various anti-epidemic supplies valued at hundreds of thousands of RMB to support frontline workers in Shanghai during the COVID-19 outbreak[125].

Financial Performance - The company reported a total share capital of 720,146,333 shares, with a cash dividend of RMB 0.50 per 10 shares for all shareholders [7]. - The company has not experienced significant performance declines or losses, indicating stable financial health [5]. - The company's operating revenue for 2021 was ¥1,268,579,510.95, representing a 19.50% increase compared to ¥1,061,574,380.03 in 2020 [21]. - The net profit attributable to shareholders in 2021 was ¥161,773,106.85, a significant turnaround from a loss of ¥126,536,626.06 in 2020, marking a 227.85% increase [21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥80,679,566.77, up 149.67% from a loss of ¥162,423,497.06 in 2020 [21]. - The net cash flow from operating activities increased by 32.72% to ¥378,155,561.13 in 2021, compared to ¥284,922,007.78 in 2020 [21]. - The total assets at the end of 2021 were ¥3,509,475,704.32, a decrease of 4.65% from ¥3,680,801,103.97 at the end of 2020 [21]. - The net assets attributable to shareholders increased by 3.42% to ¥2,733,520,373.23 at the end of 2021, compared to ¥2,643,042,773.40 at the end of 2020 [21]. - The company reported a basic earnings per share of ¥0.2241 in 2021, a recovery from a loss of ¥0.1750 in 2020, reflecting a 228.06% increase [21]. - The company’s weighted average return on equity improved to 6.00% in 2021, compared to -4.77% in 2020 [21]. Corporate Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the annual report, ensuring no misleading statements or omissions [4]. - The company maintains a commitment to corporate governance and social responsibility, as outlined in the report [9]. - The company is subject to special industry disclosure requirements due to its operations in the medical device sector [6]. - The company has established a dedicated investor relations team to facilitate communication with stakeholders [19]. - The company emphasizes strict quality control, investing significantly in quality management teams and training to maintain high product standards [48][49]. - The company is committed to ensuring the accuracy of its financial reporting and maintaining transparency with stakeholders [69][70]. Research and Development - The company is actively involved in research and development of minimally invasive surgical products, enhancing its product offerings [15]. - The company is focusing on developing minimally invasive orthopedic products, particularly through its dual-brand strategy with Aideer [36]. - The company is actively investing in research and development to enhance product offerings and improve surgical outcomes [60]. - R&D investment totaled CNY 74.25 million, an increase of CNY 18.35 million or 32.82% year-on-year, accounting for 5.85% of revenue, up 0.58 percentage points [103]. - The company is focusing on research and development to improve existing products and create new solutions for orthopedic applications [84]. - The company is committed to ongoing research and development to enhance its product portfolio and maintain market relevance [63][66]. Market Strategy and Expansion - The company is actively expanding its distribution channels and partnerships with major hospitals to enhance its market share in the medical device sector [41]. - The company has successfully penetrated the local hospital market, expanding its customer base beyond tier-three hospitals [43]. - The company aims to enhance profitability by controlling costs and improving operational efficiency in response to potential negative impacts from centralized procurement policies [34]. - The company plans to closely monitor the centralized procurement process and adjust its business strategies accordingly to mitigate the impact of these policies [33]. - The company is focusing on expanding its product offerings in the orthopedic market, as evidenced by the variety of plates listed in the procurement results [56][57][58]. - The company aims to strengthen its competitive position through strategic partnerships and potential acquisitions in the orthopedic sector [60]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach [69][70]. Product Development and Innovation - The company has expanded its product line from a single spinal product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products [36]. - The company has established a joint venture with TECRES S.P.A to develop advanced bone cement products, enhancing its product offerings in the orthopedic sector [37]. - The company has optimized its sales model and marketing system in response to orthopedic centralized procurement policies, improving its core competitiveness [38]. - The company is focusing on expanding its product offerings in the locking plate category, with multiple new designs launched in 2021 [72]. - The company is actively pursuing technological advancements in its product designs, as evidenced by the variety of locking plates introduced [62]. - The company is likely to benefit from the growing demand for advanced orthopedic solutions, as indicated by the variety of products offered [88]. Financial Challenges and Risks - The company faced significant price reductions in orthopedic consumables due to centralized procurement policies, with average price drops reaching up to 89.45% for certain products [33]. - The company has recognized a goodwill impairment provision of CNY 149.26 million due to significant price reductions in orthopedic trauma products following centralized procurement initiatives [189]. - The company is likely to explore further market expansion opportunities given the introduction of new product lines in the orthopedic sector [72]. - The company has implemented strict accounts receivable management to mitigate risks associated with large receivables and potential collection issues [192]. - The company is facing risks from centralized procurement policies that could impact sales if it fails to win bids in certain regions [187]. Operational Performance - The company achieved operating revenue of 1,268.58 million yuan, an increase of 19.50% compared to the previous year [97]. - The overall operating performance showed significant growth, driven by the recovery in outpatient and surgical volumes post-pandemic [98]. - The company has established a comprehensive platform focusing on high-value medical devices, particularly in the orthopedic field [106]. - The company’s revenue from the East China market reached CNY 542.41 million, a significant increase of 86.74% year-on-year [112]. - The company reported a significant increase in other manufacturing expenses by 33.91% year-on-year, totaling ¥31,647,105.37 [118]. Acquisitions and Investments - The company plans to acquire 100% equity of Elliquence, LLC for USD 77.15 million (approximately CNY 49.50 million) to enhance its international strategy [143]. - The company completed the payment for the acquisition of Elliquence, LLC, with the total transaction price settled as per the agreement [143]. - The company completed the acquisition of 51% of Guoyao Jieno Medical Services Co., entering the third-party disinfection center medical service field, and plans to expand capital through industry investment funds [170]. - The company has completed a capital increase of CNY 12 million in Dongzhi Medical, raising its stake to 24.13% [106]. - The company holds a 55% equity stake in Aideer, with a book value of CNY 404,564,765 as collateral for loans [147]. Regulatory and Compliance Issues - The company has obtained all necessary licenses for medical device production and operations, with a low likelihood of failing to renew these licenses in the future [183]. - The company has not faced any product liability claims or related legal issues since its establishment, thanks to a robust quality control system [184]. - The company is committed to enhancing its governance structure and compliance with regulatory requirements to promote healthy development [197]. - The company held 1 annual general meeting and 4 extraordinary general meetings during the reporting period [199]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements [200].